Format

Send to

Choose Destination
See comment in PubMed Commons below
Oncoimmunology. 2012 Jul 1;1(4):560-562.

Immuno-targeting of pancreatic cancer stem cells: A new therapeutic strategy against a devastating disease?

Author information

1
Stem Cells & Cancer Group; Clinical Research Programme; Spanish National Cancer Research Centre (CNIO); Madrid, Spain.

Abstract

Pancreatic cancer is a highly aggressive and deadly disease harboring a distinct population of cancer stem cells (CSC) that is not affected by conventional therapies. A new therapeutic approach using the EpCAM/CD3-bispecific antibody MT110 is capable of activating and redirecting cytotoxic T cells to eliminate primary human pancreatic cancer stem cells, which resulted in long-term survival of preclinical xenografts models.

PMID:
22754787
PMCID:
PMC3382890
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for PubMed Central
    Loading ...
    Support Center